Pfizer (PFE), Sanofi (SNY), Novartis (NVS), and GSK (GSK) are among the drug makers planning price increases for at least 350 branded drugs starting in January, Reuters reported Wednesday, citing data from 3 Axis Advisors.

The scheduled hikes exceed the 250 drug price increases reported at the same time last year and include vaccines for COVID, RSV, and shingles, despite pressure from the Trump administration to lower prices.

Pfizer leads the volume of increases with plans to raise prices on roughly 80 products, including a 15% hike for its COVID-19 vaccine Comirnaty, but with most of its adjustments remaining below 10%, Reuters reported.

GSK intends to implement price rises between 2% and 8.9% for around 20 medications and vaccines, according to the report.

Conversely, some manufacturers plan to reduce prices on nine drugs, including a cut of more than 40% for the diabetes treatment Jardiance following Medicare negotiations, the media outlet reported.

Pfizer, Sanofi, Novartis, and GSK did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)